Impact of antiphospholipid syndrome on disease characteristics and outcome in patients with systemic lupus erythematosus

Zucchi, 2022, One year in review 2022: Systemic lupus erythematosus, Clin Exp Rheumatol, 40, 4, 10.55563/clinexprheumatol/nolysy El Hadidi, 2018, Characteristics of systemic lupus erythematosus in a sample of the Egyptian population: A retrospective cohort of 1109 patients from a single center, Lupus, 27, 1030, 10.1177/0961203317751856 Gheita, 2021, Adult systemic lupus erythematosus in Egypt: The nation-wide spectrum of 3661 patients and world-wide standpoint, Lupus, 30, 1526, 10.1177/09612033211014253 To, 2005, Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus?, Arthritis Rheum, 52, 4003, 10.1002/art.21414 Levine, 2002, The antiphospholipid syndrome, N Engl J Med, 346, 752, 10.1056/NEJMra002974 Cavazzana I, Andreoli L, Limper M, Franceschini F, Tincani A. 2 Update on antiphospholipid syndrome: ten topics in 2017.Curr Rheumatol Rep.20(3):15. Andreoli, 2012, Beyond the ‘‘syndrome’’: Antiphospholipid antibodies as risk factors, Arthritis Rheum, 64, 342, 10.1002/art.33341 İlgen, 2018, Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus, Lupus, 27, 665, 10.1177/0961203317734924 Laskin, 2005, Antiphospholipid syndrome in systemic lupus erythematosus: Is the whole greater than the sum of its parts?, Rheum Dis Clin North Am, 31, 255, 10.1016/j.rdc.2005.01.011 Ruiz-Irastorza, 2004, High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus, Arch Intern Med, 164, 77, 10.1001/archinte.164.1.77 Taraborelli, 2016, The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus, Lupus, 25, 1365, 10.1177/0961203316637431 Gheita, 2019, Rheumatology in Egypt: Back to the future, Rheumatol Int, 39, 1, 10.1007/s00296-018-4192-0 Petri, 2012, Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus, Arthritis Rheum, 64, 2677, 10.1002/art.34473 Miyakis, 2006, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost, 4, 295, 10.1111/j.1538-7836.2006.01753.x Gladman, 2002, Systemic lupus erythematosus disease activity index 2000, J Rheumatol, 29, 288 Yee, 2011, The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients, Rheumatology, 50, 982, 10.1093/rheumatology/keq376 Gladman, 1996, The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus, Arthritis Rheum, 39, 363, 10.1002/art.1780390303 Farzaneh-Far, 2006, Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus, Arthritis Rheum, 54, 3918, 10.1002/art.22265 Riancho-Zarrabeitia, 2020, Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality, Lupus, 29, 1556, 10.1177/0961203320950477 Gheita, 2018, Anti-dsDNA titre in female systemic lupus erythematosus patients: relation to disease manifestations, damage and antiphospholipid antibodies, Lupus, 27, 1081, 10.1177/0961203318760209 Gaber, 2012, Comparative study of kidney affection in SLE patients with and without antiphospholipid syndrome, Egypt Rheumatol, 34, 51, 10.1016/j.ejr.2012.01.001 Morad, 2022, Primary and secondary antiphospholipid syndrome characteristics in an Egyptian cohort, Egypt Rheumatol, 44, 373, 10.1016/j.ejr.2022.07.006 Crnjak, 2018 Girardi, 2003, Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome, J Clin Invest, 112, 1644, 10.1172/JCI200318817 Artim-Esen, 2014, Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center, J Rheumatol, 41, 1304, 10.3899/jrheum.130984 Taraborelli, 2016, The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus, Reumatismo, 68, 137, 10.4081/reumatismo.2016.891 Deák, 2014, Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome, Lupus, 23, 913, 10.1177/0961203314531839 Parodis, 2016, Antiphospholipid antibodies in lupus nephritis, PLoS One, 11, e0158076, 10.1371/journal.pone.0158076 Erton, 2022, Pregnancy outcomes in antiphospholipid antibody positive patients: Prospective results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (‘Registry’), Lupus Sci Med, 9, e000633, 10.1136/lupus-2021-000633 Bundhun, 2018, Arterial/venous thrombosis, fetal loss and stillbirth in pregnant women with systemic lupus erythematosus versus primary and secondary antiphospholipid syndrome: A systematic review and meta-analysis, BMC Preg Childbirth, 18, 212, 10.1186/s12884-018-1850-x Kaiser, 2009, Risk and protective factors for thrombosis in systemic lupus erythematosus: Results from a large, multi-ethnic cohort, Ann Rheum Dis, 68, 238, 10.1136/ard.2008.093013 Franco, 2014, The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians, PLoS ONE, 9, e110242, 10.1371/journal.pone.0110242 Bazzan, 2015, Systemic lupus erythematosus and thrombosis, Thromb J, 13, 1, 10.1186/s12959-015-0043-3 Raymond, 2018, Hypocomplementemia as a risk factor for organ damage accrual in patients with systemic lupus erythematosus, J Immunol Res, 8051972 Conti, 2016, The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: Results from a monocentric cohort, Lupus, 25, 719, 10.1177/0961203315627199 Goncalves, 2015, Characterization of damage in Portuguese lupus patients: Analysis of a national lupus registry, Lupus, 24, 256, 10.1177/0961203314555172 Bonakda, 2011, Evaluation of damage index and its association with risk factors in patients with systemic lupus erythematosus, J Res Med Sci, 16, S427 Legge, 2016, Predictors of organ damage progression and effect on health-related quality of life in systemic lupus erythematosus, J Rheumatol, 43, 1050, 10.3899/jrheum.150985 Petri, 2012, Predictors of organ damage in systemic lupus erythematosus: The Hopkins Lupus Cohort, Arthritis Rheum, 64, 4021, 10.1002/art.34672 Pinto-Peñaranda, 2018, Antiphospholipid antibodies, steroid dose, arterial hypertension, relapses, and late-onset predict organ damage in a population of Colombian patients with systemic lupus erythematosus, Clin Rheumatol, 37, 949, 10.1007/s10067-017-3927-8